Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|October 2, 2013
- Pharmaceutical Technology-10-02-2013
- Volume 37
- Issue 10
Software Improves Monitoring of Pharmaceutical Ingredients
Author(s)Melanie Sena
Software Improves Monitoring of Pharmaceutical Ingredients
Dissolution Workstation Software provides updated data integration, method change control, and instrument monitoring for controlling multiple dissolution systems. The software supports laboratory capabilities to build, edit, search, retrieve, execute, and archive all dissolution methods and test reports from a single interface. The software consolidates and maintains electronic data in one location, with options for exporting information into a laboratory information management system or into business tools such as SAP Crystal Reports or Microsoft Excel. Dissolution Workstation Software organizes, executes, and manages methods and information for all Agilent dissolution equipment, including the Agilent 708-DS, 709-DS, BIO-DIS, Apparatus 7, and dissolution sampling systems.
Articles in this issue
almost 13 years ago
Q&A with Amie Gehris, Dow Water and Process Solutionsalmost 13 years ago
Unraveling the Mystery of Ireland's Pharm-Attractionsalmost 13 years ago
Report from: Middle East and North Africaalmost 13 years ago
Maintaining and Verifying the Cold Chainalmost 13 years ago
Ensuring Compliance with Drug Accountability Requirementsalmost 13 years ago
The Expense of Vision in Outsourcingalmost 13 years ago
LCMS-8050 Mass Spectrometer Increases Quality Analysisalmost 13 years ago
Tracking Quality in Drug Manufacturingalmost 13 years ago
USP Seeks Input on Standards for Plastic Packaging Systemsalmost 13 years ago
RheocalcT Software Tests Parameters and Data CollectionRelated to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
PharmTech’s Weekly Roundup—September 25, 2026
3
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
4
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
5